Corcept's ALS Drug Linked to 87% Reduction in Risk of Death

Corcept Therapeutics has reported a striking clinical signal for its amyotrophic lateral sclerosis drug candidate — an 87% reduction in the risk of death in the patient population studied. The result is one the biotech hopes to replicate in an upcoming Phase 3 trial.  ALS is one of the most devastating and rapidly progressing neurological conditions in medicine, with a median survival of two to five years from diagnosis and no currently available therapy that significantly alters the disease course for most patients. A result of this magnitude, if confirmed at Phase 3 scale, would represent one of the most significant advances in ALS treatment in the field's history.

The drug targets the glucocorticoid receptor — a biological pathway that Corcept has been working in for years through its approved drug mifepristone, which is used in Cushing's syndrome. The hypothesis for ALS is that modulating this receptor reduces the neuroinflammation that drives motor neuron degeneration — a mechanistic rationale that is distinct from the approaches taken by existing ALS therapies and that may explain why the clinical signal is as strong as the early data suggests.

The 87% figure will appropriately face scrutiny pending Phase 3 confirmation — early-phase ALS data has historically been difficult to replicate at larger scale, and the field has experienced high-profile late-stage disappointments in recent years. But the magnitude of the signal is sufficient to generate genuine attention from the neurology community and from patients for whom the current standard of care offers limited hope. The Phase 3 design and timeline are expected to be announced alongside the formal publication of the Phase 2 data.